Literature DB >> 21720167

A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines.

L I Partecke1, M Sendler, A Kaeding, F U Weiss, J Mayerle, A Dummer, T D Nguyen, N Albers, S Speerforck, M M Lerch, C D Heidecke, W von Bernstorff, A Stier.   

Abstract

BACKGROUND/AIMS: To develop a clinically relevant immunocompetent murine model to study pancreatic cancer using two different syngeneic pancreatic cancer cell lines and to assess MRI for its applicability in this model.
METHODS: Two cell lines, 6606PDA and Panc02, were employed for the experiments. Cell proliferation and migration were monitored in vitro. Matrigel™ was tested for its role in tumor induction. Tumor cell growth was assessed after orthotopic injection of tumor cells into the pancreatic head of C57/BL6 mice by MRI and histology.
RESULTS: Proliferation and migration of Panc02 were significantly faster than those of 6606PDA. Matrigel did not affect tumor growth/migration but prevented tumor cell spread after injection thus avoiding undesired peritoneal tumor growth. MRI could reliably monitor longitudinal tumor growth in both cell lines: Panc02 had a more irregular finger-like growth, and 6606PDA grew more spherically. Both tumors showed local invasiveness. Histologically, Panc02 showed a sarcoma-like undifferentiated growth pattern, whereas 6606PDA displayed a moderately differentiated glandular tumor growth. Panc02 mice had a significantly shorter (28 days) survival than 6606PDA mice (50 days).
CONCLUSION: This model closely mimics human pancreatic cancer. MRI was invaluable for longitudinal monitoring of tumor growth thus reducing the number of mice required. Employing two different cell lines, this model can be used for various treatment and imaging studies.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720167     DOI: 10.1159/000329413

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  23 in total

1.  Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.

Authors:  Kun Shi; Helene Damhofer; Joost Daalhuisen; Marieke Ten Brink; Dick J Richel; C Arnold Spek
Journal:  Mol Med       Date:  2017-02-06       Impact factor: 6.354

2.  Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.

Authors:  Jingjing Sun; Zhuoya Wan; Yichao Chen; Jieni Xu; Zhangyi Luo; Robert A Parise; Dingwei Diao; Pengfei Ren; Jan H Beumer; Binfeng Lu; Song Li
Journal:  Acta Biomater       Date:  2020-01-28       Impact factor: 8.947

Review 3.  Real-time intravital imaging of cancer models.

Authors:  A Zomer; E Beerling; E J Vlug; J van Rheenen
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

4.  Bioluminescent orthotopic model of pancreatic cancer progression.

Authors:  Ming G Chai; Corina Kim-Fuchs; Eliane Angst; Erica K Sloan
Journal:  J Vis Exp       Date:  2013-06-28       Impact factor: 1.355

Review 5.  Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis.

Authors:  Wanglong Qiu; Gloria H Su
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

6.  Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel.

Authors:  Yong-Jian Jiang; Chong-Lek Lee; Qiang Wang; Zhong-Wen Zhou; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice.

Authors:  Benson Chellakkan Selvanesan; Dinesh Chandra; Wilber Quispe-Tintaya; Arthee Jahangir; Ankur Patel; Kiran Meena; Rodrigo Alberto Alves Da Silva; Madeline Friedman; Lisa Gabor; Olivia Khouri; Steven K Libutti; Ziqiang Yuan; Jenny Li; Sarah Siddiqui; Amanda Beck; Lydia Tesfa; Wade Koba; Jennifer Chuy; John C McAuliffe; Rojin Jafari; David Entenberg; Yarong Wang; John Condeelis; Vera DesMarais; Vinod Balachandran; Xusheng Zhang; Ken Lin; Claudia Gravekamp
Journal:  Sci Transl Med       Date:  2022-03-23       Impact factor: 19.319

8.  Impact of diabetes type II and chronic inflammation on pancreatic cancer.

Authors:  Dietmar Zechner; Tobias Radecke; Jonas Amme; Florian Bürtin; Ann-Christin Albert; Lars Ivo Partecke; Brigitte Vollmar
Journal:  BMC Cancer       Date:  2015-02-13       Impact factor: 4.430

9.  Tissue tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and in vivo.

Authors:  Lars Ivo Partecke; Katja Evert; Jan Haugk; Friderike Doering; Lars Normann; Stephan Diedrich; Frank-Ulrich Weiss; Matthias Evert; Nils Olaf Huebner; Cristin Guenther; Claus Dieter Heidecke; Axel Kramer; René Bussiahn; Klaus-Dieter Weltmann; Onur Pati; Claudia Bender; Wolfram von Bernstorff
Journal:  BMC Cancer       Date:  2012-10-15       Impact factor: 4.430

10.  Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer.

Authors:  Dietmar Zechner; Florian Bürtin; Jonas Amme; Tobias Lindner; Tobias Radecke; Stefan Hadlich; Jens-Peter Kühn; Brigitte Vollmar
Journal:  Cell Biosci       Date:  2015-08-28       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.